Cystic Fibrosis and Treatment with ψ–Hamzah.

Abstract This article presents an advanced theoretical framework for the treatment of Cystic Fibrosis (CF) using the ψ–Hamzah model, a dynamic fractional-order system that leverages fractional calculus and biological memory. The proposed treatment method does not rely on gene therapy but instead utilizes a fractional dynamic model to restore the function of CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) in epithelial cells, the pancreas, and the intestines, while simultaneously regulating immune responses and reducing chronic inflammation. The treatment is modeled using a set of complex equations that integrate memory-based fractional derivatives to describe the recovery dynamics of CFTR, the interaction of molecular signaling pathways (e.g., IL-8), and multi-organ feedback mechanisms. This model provides a comprehensive approach to restoring the functional homeostasis of the respiratory, digestive, and immune systems. In Stage 1 to 7, the system's dynamic behaviors are examined, beginning with the recovery of ψ (a symbolic representation of biological homeostasis) via fractional differentiation, followed by the simulation of molecular signaling pathways like IL-8 in Stage 8, which influences chronic inflammation in CF. The multi-organ coordination of these dynamics is analyzed in Stage 9, demonstrating a global ψ homeostasis that extends across all affected organs. Stages 10 and 11 involve system-wide coordination through feedback loops between organs, leading to synchronized immune and CFTR recovery, followed by the final patentable results and clinical implications. The computational framework, implemented in Python, leverages numerical techniques like Caputo fractional derivatives and ODE solvers to simulate the model across 11 stages, simulating the dynamics of CF treatment in real-world conditions. The outcome of this research suggests that fractional dynamic models like the ψ–Hamzah model hold promise as an innovative approach to treating CF without genetic modification, offering significant therapeutic potential in clinical practice. This model's ability to model complex, multi-scale systems through mathematical and computational techniques opens new avenues for exploring non-genetic therapies for CF and potentially other chronic diseases with similar pathological mechanisms.